Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 31 Show results per page	View Search Criteria \| Help With Results


1.		Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				Not specified				Other				HSC-MS-06-0478 OSP-24412, NCT00581425


2.		Thalidomide/Dexamethasone Vs MP for Induction Therapy and Thalidomide/Intron A Vs Intron A for Maintenance Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 and over				Other				01-002-0601 NCT00205751


3.		ABR-217620 With Interferon-Alpha (IFN-Alpha) Compared to IFN-Alpha Alone in Patients With Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				06762004 NCT00420888

Last Modified: 1/14/2009 First Published: 12/1/1998


4.		Phase III Randomized Adjuvant Study of High-Dose Interferon alfa-2b Therapy in Patients With Stage II or III Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-1697 SWOG-E1697, CALGB-500103, CAN-NCIC-ME10, COG-E1697, E1697, NCT00003641, ME10

Last Modified: 11/27/2006 First Published: 2/21/2003


5.		Phase III Randomized Study of Imatinib Mesylate Alone or With Interferon alfa or Low-Dose Cytarabine Versus Interferon alfa Standard Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				Other				III-MK-CML-IV EU-20248, NCT00055874


6.		SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				A6181034 NCT00083889


7.		Rituximab After Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				60 and over				Other				MCL2004-1 NCT00209209

Last Modified: 2/16/2007 First Published: 10/1/1999


8.		Phase I/II Study of Cisplatin, Gemcitabine, Interferon alfa, and Long-Duration, Low-Temperature Whole Body Hyperthermia (LL-WBH) in Patients with Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				UTHSC-MS-99116 NCI-V99-1561, NCT00004063

Last Modified: 11/14/2008 First Published: 10/25/2004


9.		Phase I/II Study of Vaccine Comprising a HER2/neu-Positive Allogeneic Tumor Cell Line Transfected With the Sargramostim (GM-CSF) Gene in Combination With Low-Dose Interferon alfa and Low-Dose Cyclophosphamide in Patients With HER2/neu-Positive Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				WRI-GEV-007 NCT00095862, WRI-GEV-007


10.		Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				immatureDC- HMO-CTIL NCT00278018

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute